President Trump has initiated a discussion where he questions if the use of the term "Artificial Intelligence" is appropiate. If a woman or a man is able to compute complicated mathematics or to resolve and answer very complex scientific questions within outstanding short time periods or even derives essential new scientific insights or laws she or he is usually called genius. What is now understood as "Artificial Intelligence" or "AI" software is usually the product of such genius who is a curious person with the target to economize the process of problem resolving and gaining new insights. When such software is able to produce meaningful knowledge according to the rules set by its creator when computing the solutions of complicated mathematic or physical problems or answering complex questions or developing even new insights based on an extraordinary method or theory, and that for or also with the help of masses of data and in very short time periods, it should be indeed rather named "genius" as its creator is not "artificial". Moreover, if a golf player wins the U.S. Open, it is never the clubs especially manufactured for him to win the tournament but he himself.
SCHOLZ DataBank generates already for many years based on a permanently revised and supplemented core of medical-pharmaceutical knowledge with each update a huge complex database, with partially revised, partially completely new content, which is produced to a substantial extent by automated language processing. This database with its Adverse Drug Risk Control Panel (ADR CP) helps doctors and pharmacists to check medications for hundred thousands of drug drug interactions and provides within seconds for billions of polypharmacy scenarios and their multiple drug drug interactions (MDDI) answers how the patients`s vital signs and drug safety might be affected and in case be optimized whereby individual patient data such as Chronic Kidney Disease stages (CKD) and pharmacogenetic properties are included in the analysis, too. As long as such system breathes the spirit of its creator it does not represent "Artificial Intelligence", it is different and more, and as President Trump evidently and aptly assumes, rather and why not "Genius Intelligence".
SCHOLZ DataBank generates already for many years based on a permanently revised and supplemented core of medical-pharmaceutical knowledge with each update a huge complex database, with partially revised, partially completely new content, which is produced to a substantial extent by automated language processing. This database with its Adverse Drug Risk Control Panel (ADR CP) helps doctors and pharmacists to check medications for hundred thousands of drug drug interactions and provides within seconds for billions of polypharmacy scenarios and their multiple drug drug interactions (MDDI) answers how the patients`s vital signs and drug safety might be affected and in case be optimized whereby individual patient data such as Chronic Kidney Disease stages (CKD) and pharmacogenetic properties are included in the analysis, too. As long as such system breathes the spirit of its creator it does not represent "Artificial Intelligence", it is different and more, and as President Trump evidently and aptly assumes, rather and why not "Genius Intelligence".